Effect of corticotherapy on interleukin-8 and -12 and nitric oxide production during Behçet and idiopathic uveitis;Effet de la corticothérapie sur la production des interleukines 8, 12 et du monoxyde d'azote au cours des uvéites Behçet et idiopathique

Journal Francais d'Ophtalmologie

Volumn 31, Issue 4, 2008, Pages 387-395

  Belguendouz, H ^a   Messaoudene, D ^a   Hartani, D ^b   Chachoua, L ^c   Ahmedi, M L ^a   Lahmar Belguendouz, K ^a   Lahlou Boukoffa, O ^d   Touil Boukoffa, C ^a  

^a UNIVERSITY OF SCIENCES AND TECHNOLOGY HOUARI BOUMEDIENE   (Algeria)

^b CHU Mustapha   (Algeria)

^c CHU Naffissa Hamoud   (Algeria)

^d Centre Hospitalier Universitaire de Annaba   (Algeria)

Author keywords

Beh et uveitis; Idiopathic uveitis; IL 12; IL 8; Nitric oxide

Indexed keywords

EID: 43949101383     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0181-5512(08)71433-5     Document Type: Article

References (53)

1. Flament J. Ophtalmologie. Pathologie de l’œil. Paris : Éd Masson ; 2002, p. 133-41.
2. Brézin A. Sémiologie et classification des uvéites. La revue du praticien, 1999;49:1982-98.
3. Chaine G. Ophtalmologie. Paris : Éd doin ; 2000, p. 87-103.
4. McCluskey PJ, Towler HMA, Lightman S. Management of chronic uveitis. BMJ, 2000;320:555-8.
5. Whitcup SM. The double-edged ocular immune response: the Cogan lecture. Invest Ophthalmol Vis Sci, 2000;41:3243-8.
6. Cassoux N, Fardeau C, Lehoang P. Manifestations oculaires de la maladie de Behçet. Ann Med Interne, 1999;150:529-34.
7. Yato H, Matsumoto Y. CD 56+ T cells in the peripheral blood of uveitis patients. Br J Ophthalmol, 1999;83:1386-8.
8. Huhtinen M, Repo H, Laasila K, Jansson SE, Kautiainen H, Karma A, et al . Systemic inflammation and innate immune response in patients with previous anterior uveitis. Br J Ophthalmol, 2002;86:412-7.
9. Murray PI, Hoekzema R, van Haren MA, de Hon FD, Kijlstra A. Aqueous humor interleukin-6 levels in uveitis. Invest Ophthalmol Vis Sci, 1999;31:917-20.
10. Taguchi C, Sugita S, Tagawa Y, Nishihira J, Mochizuki M. Macrophage migration inhibitory factor in ocular fluids of patients with uveitis. Br J Ophthalmol, 2001;85:1367-71.
11. Murphy CC, Duncan L, Forrester JV, Dick AD. Systemic CD4+ T cell phenotype and activation status in intermediate uveitis. Br J Ophthalmol, 2004;88:412-6.
12. Whittle RM, Wallace GR, Whiston RA, Dumonde DC, Stanford MR. Human antiretinal antibodies in toxoplasma retinochoroiditis. Br J Ophthalmol, 1998;82:1017-21.
13. de Smet MD, Bitar G, Mainigi S, Nussenblatt RB. Human S-antigen determinant recognition in uveitis. Invest Ophthalmol Vis Sci, 2001;42:3233-8.
14. Deeg CA, Kaspers B, Gerhards H, Thurau SR, Wollanke B, Wildner G. Immune responses to retinal autoantigens and peptides in equine recurrent uveitis. Invest Ophthalmol Vis Sci, 2004;42:393-8.
15. Guenane H, Hartani D, Chachoua L, Lahlou-Boukoffa OS, Mazari F, Touil-Boukoffa C. Production des cytokines Th1/Th2 et du monoxyde d’azote au cours de l’uvéite « Behçet » et de l’uvéite idiopathique. J Fr Ophtalmol, 2006;29:146-52.
16. Mirza GE, Karakuçuk S, Er M, Gungormus N, Karakuçuk I, Saraymen R. Tear nitrite and nitrate levels as nitric oxide end products in patients with Behçet’s disease and non-Behçet’s uveitis. Ophthalmic Res, 2001;33:48-51.
17. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity, 2000;12:121-7.
18. Williams G, Borkakoti N, Bottomley GA, Cowan I, Fallowfield AG, Jones PS, et al . Mutagenesis studies of interleukin-8. Identification of a second epitope involved in receptor binding. J Biol Chem, 1996;271:9579-86.
19. Moncada S. Nitric oxide: discovery and impact on clinical medicine. J Roy Soc Med, 1999;92:164-9.
20. Arya SK, Wong-Staal F, Gallo RC. Dexamethasone-mediated inhibition of human T cell growth factor and γ-Interferon messenger RNA. J Immunol, 1984;133:273-6.
21. Adcock IM, Nasuhara Y, Stevens DA, Barnes PJ. Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targetting of NF-kB and lack of I-kB involvement. Br J Pharmacol, 1999;127:1003-11.
22. Nissen RM, Yamamoto KR. The glucocorticoid receptor inhibits NFκB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes & Developement, 2000;14:2314-29.
23. Ashwell JD, Lu FW, Vacchio MS. Glucocorticoids in T cell development and function. Annu Rev Immunol, 2000;18:309-45.
24. Franchimont D, Galon J, Gadina M, Visconti R, Zhou Y, Aringer M, et al . Inhibition of Th1 immune response by glucocorticoids: dexamethasone selectively inhibits IL-12-induced stat4 phosphorylation in T lymphocytes. J Immunol, 2000;164:1768-74.
25. Bodaghi B, Gendron G, Wechsler B, Terrada C, Cassoux N, Huong du LT, et al . Efficacy of interferon alpha in the treatment of refractory and sight-threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophtalmol, 2007;91:335-9.
26. Tugal-Tutkun I, Güney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behçet uveitis. Graefes Arch Clin Exp Ophthalmol, 2006;244:1692-5.
27. International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet, 1990;335:1078-80.
28. Murphy PM, Baggiolini M, Charo IF, Hébert CA, Horuk R, Matsushima K, et al . International Union of Pharmacology. XXII. Nomenclature for Chemokine Receptors. Pharmacol Rev, 2000;52:145-76.
29. Tugal-Tutkun I, Urgancioglu M, Foster CS. Immunopathologic study of the conjunctiva in patients with Behçet disease. Ophthalmology (Rochester MN), 1995;102:1660-8.
30. Hashida N, Ohguro N, Yamamoto S, Nakagawa Y, Tano Y. Unusual neutrophil infiltration under the soft contact lens in a patient with Behçet’s disease. Jpn J Ophthalmol, 2003;47:469-72.
31. Carletto A, Pacor ML, Biasi D, Caramaschi P, Zeminian S, Bellavite P, et al . Changes of neutrophil migration without modification of in vitro metabolism and adhesion in Behcet’s disease. J Rheumatol, 1997;24:1332-6.
32. Eksioglu-Demiralp E, Direskeneli H, Kibaroglu A, Yavuz S, Ergun T, Akoglu T. Neutrophil activation in Behcet’s disease. Clin Exp Rheumatol, 2001;19(Suppl 24):S19-24.
33. Lit LC, Wong CK, Tam LS, Li EK, Lam CW. Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann Rheum Dis, 2006;65:209-15.
34. Ben Ahmed M, Houmam H, Miled M, Dellagi, Louzir H. Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behçet’s disease. Arthritis rheum, 2004;50:2291-5.
35. Koarada S, Haruta Y, Tada Y, Ushiyama O, Morito F, Ohta A, et al . Increased entry of CD4+ T cells into the Th1 cytokine effector pathway during T-cell division following stimulation in Behcet’s disease. Rheumatology, 2004;43:843-51.
36. Dugas B, Debré P, Monocada S. Nitric oxide, a vital poison inside the immune response and inflammatory network. Res Immunol, 1995;146:664-70.
37. Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, Gubler U, et al . The interleukin-12/interleukin-12- receptor system: role in normal and pathologic immune responses. Annu Rev Immunol, 1998;16:495-521.
38. Romani L, Puccetti P, Bistoni F. Interleukin-12 in Infectious Diseases. Clin Microbiol Rev, 1997;10:611-36.
39. Hiroshi K, Jun-Ichi S, Kusuki N, Takayuki S, Masahiko U. Clonally accumulating T cells in the anterior chamber of Behçet disease. Am J Ophthalmol, 2000;130:243-5.
40. Kaburaki T, Fujino Y, Kawashima H, Merino G, Numaga J, Chen J, et al . Plasma and whole-blood chemokine levels in patients with Behcet’s disease. Graefe’s Arch Clin Exp Ophthalmol, 2003;241: 353-8.
41. Mi-La C, Ju-Young K, Hyeok-Jae KO, Young-Hoon K, Wan-Uk K, Chul-Soo C, et al . The MCP-1 promoter — 2,518 polymorphism in Behcet’s disease: Correlation between allele types, MCP-1 production and clinical symptoms among Korean patients. Autoimmunity, 2004;37:77-80.
42. Stellato C. Post-transcriptional and nongenomic effects of glucocorticoids. Proceedings of the American Thoracic Society, 2004;1:255-3.
43. Tobler A, Meier R, Seitz M, Dewald B, Baggiolini M, Fey MF. Glucocorticoids Downregulate Gene Expression of GM-CSF, NAP-l/IL-S, and IL-6, but not of M-CSF in Human Fibroblasts. Blood, 1992;79:45-51.
44. Mukaida N, Morita M, Ishikawa Y, Rice N, Okamoto S. Novel Mechanism of Glucocorticoid-mediated Gene Repression. Nuclear factor-KB is target for glucocorticoid-mediated interleukin 8 gene repression. J Biol Chem, 1994;269:13289-95.
45. Walker G, Pfeilschifter J, Kunz D. Mechanisms of Suppression of Inducible Nitric-oxide Synthase (iNOS) Expression in Interferon (IFN)-γ-stimulated RAW 264.7 Cells by Dexamethasone. Evidence for glucocorticoid-induced degradation of iNOS protein by calpain as a key step in post-transcriptional regulation. J Biol Chem, 1997;272:16679-87.
46. Ahuja SK, Lee JC, Murphy PM. CXC chemokines bind to unique sets of selectivity determinants that can function independently and are broadly distributed on multiple domains of human interleukin-8 receptor B. Determinants of high affinity binding and receptor activation are distinct. J Biol Chem, 1996;271:225-32.
47. Christopherson II K, Hromas R. Chemokine regulation of normal and pathologic immune responses. Stem Cells, 2001;19:388-96.
48. Williams L, Jarai G, Smith A, Finan P. IL-10 expression profiling in human monocytes. J Leukoc Biol, 2002;72:800-9.
49. Woltman AM, van der Kooij SW, de Fijter JW, van Kooten C. Maturation-resistant dendritic cells induce hyporesponsiveness in alloreactive CD45RA+ and CD45RO+ T-cell populations. Am J Transplant, 2006;6:2580-91.
50. Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K. Cytokine profile in Behçet’s disease patients. Relationship with disease activity. Scand J Rheumatol, 2002;31:205-10.
51. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol, 1997;15:749-95.
52. Akdeniz N, Esrefoglu M, Keles MS, Karakuzu A, Atasoy M. Serum interleukin-2, interleukin-6, tumour necrosis factor-alpha and nitric oxide levels in patients with Behcet’s disease. Ann Acad Med Singapore, 2004;33:596-9.
53. Bardak Y, Aridogan BC. The demonstration of serum interleukin 6-8, tumor necrosis factor-alpha, complement, and immunoglobulin levels in Behçet’s disease with ocular involvement, Ocul Immunol Inflamm, 2004;12:53-8.